The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
Aduhelm (Drug) Advertising and Marketing Alzheimer’s Disease Biogen Inc Cleveland Clinic Clinical Trials Drugs (Pharmaceuticals) Elderly Food and Drug Administration House Committee on Energy and Commerce House Committee on Oversight and Government Reform Labeling and Labels (Product) Maloney, Carolyn B Pallone, Frank Jr
Leave a Reply